Principles for establishment of the stem cell bank and its applications on management of sports injuries

Bao-Shi Fan 1,2,3†, Yang Liu 1,2†, Ji-Ying Zhang 1,2, You-Rong Chen 1,2, Meng Yang 1,2,3 and Jia-Kuo Yu 1,2*†

Abstract

Background: The stem cells of the stem cell banks have prominent problems for insufficient sources, easy contamination, unstable biological characteristics after serial subcultivations, and high cost.

Methods: After collecting the construction processes of the existing stem cell banks and suggestions from authoritative experts in the past 10 years, 230 reference principles were obtained, and finally, the principles of “5C” for the establishment of modern standardized stem cell banks were summarized, and their related applications on the management of sports injuries were reviewed as well.

Results: The basic principles of “5C” for the establishment of modern standardized stem cell banks include (1) principle of informed consent, (2) confidentiality principle, (3) conformity principle, (4) contamination-free principle, and (5) commonweal principle. The applications of stem cells on repairs, reconstructions, and regenerations of sports injuries were also reviewed, especially in tissue-engineered cartilage, tissue-engineered meniscus, and tissue-engineered ligament.

Conclusions: The proposal of the basic principles of “5C” is conducive to relevant stem cell researchers and clinical medical experts to build modern stem cell banks in a more standardized and efficient manner while avoiding some major mistakes or problems that may occur in the future. On this basis, stem cells from stem cell banks would be increasingly used in the management of sports injuries. More importantly, these days, getting stem cell samples are difficult in a short time, and such banks with proper legal consent may help the scientific community.

Keywords: Stem cell, Stem cell bank, Basic principle, Tissue-engineered cartilage, Tissue-engineered meniscus, Tissue-engineered ligament

Introduction

Stem cells are a group of primitive cells with the potentials of self-renewal and multidirectional differentiation, and they are also known as “universal cells” and “seed cells” [1, 2]. A stem cell bank is a platform for the large-scale collection, preparation, storage, provision, and research of stem cells, so it is also known as a “life bank” [3]. Since it is difficult to get most stem cells, the standardized production and preservation of stem cells through stem cell banks have become a mainstream trend [4]. The first international stem cell bank was established by the British Government in 2004. Since then, many stem cell banks have been established by governments or research institutions, such as the British Stem Cell Bank, the Korean NIH Stem Cell Bank [5], the Wicell Stem Cell Bank in the University of Wisconsin, and the RIKE

* Correspondence: yujiakuo@126.com
†Bao-Shi Fan and Yang Liu contributed equally to this work.
1Sports Medicine Department of the Institution of Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, No. 49 North Garden Road, Beijing 100191, China
2Institute of Sports Medicine of Peking University, No. 49 North Garden Road, Beijing 100191, China
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
N BioResource Center at RIKEN [6, 7] which are mainly for the storage and transfer of stem cell resources.

Although the researches and establishments of stem cell banks in China are late in getting started, the development momentum is rapid. Among them, the National Stem Cell Resource Center established the first clinical-level stem cell bank and clinical-level embryonic stem cell line of China in 2007, and the establishment has actively promoted the sharing of stem cell resources. In 2017, it provided over 200 batches of stem cells for more than 20 research institutions and hospitals for pre-clinical researches or basic researches, actively promoting the translation of stem cells from laboratory to clinic. At present, this center has established nearly 300 clinical-grade human embryonic stem cell lines with definite HLA matching types and nearly 2000 cell lines with different developmental potentials, laying a foundation for standardized and large-scale obtaining of functional cells for clinical application and the development of stem cell drugs. Established in 2000, Peking University Stem Cell Research Center has become a prospective research institute for basic and clinical researches and a training center for stem cell biotechnology in China. Established in 2015, Shanghai East Hospital Biobank is the first standardized biobank, integrating stem cell resources and other sample resources in China. Founded in April 2010, Boyalife is the first and the only clinical-grade stem cell bank in China that has passed the AABB Standard of the United States, the NRL Standard of the World Health Organization, and the CAP Standard of the American Society of Pathology (Table 1). Due to the complexity of building stem cell banks that requires the collaboration of ethics, sociology, medicine, bioinformatics, and many other fields, the domestic and foreign stem cell banks have not yet formed a unified principle or guideline for establishment and application [8].

Although stem cells can differentiate into different tissues and cells under certain induced microenvironments, they also tend to age under unstable storage conditions [9]. Aging has a serious impact on all cells and tissues and can cause damages to the stem cell microenvironments [10, 11].

With the increasing cases of sports injury worldwide, issues for the treatments of articular cartilage injuries and the reconstruction of the structure and function of the torn meniscus and ligament need to be put on the agenda to promote recovery of motor function [12]. In the past 20 years, great achievements have been made in the basic and clinical researches of stem cells and tissue engineering procedures in sports medicine. The most worthy of mention is that the rapid development and application of tissue-engineered cartilage (TEC), tissue-engineered meniscus (TEM), and tissue-engineered ligament (TEL) have greatly expanded the feasibility of the clinical application of stem cells in the management of sports injuries [13].

To sum up, in order to meet the needs of clinical treatment and the application markets of stem cells, it is urgent to propose the basic principles of establishing modern standardized stem cell banks. The establishment of stem cell banks and their applications on the management of sports injuries will promote the revolutionary change of sports injury management.

**Table 1** The famous stem cell bank established in the world

| Name of bank | Stem cell type          | Country     | Website and/or reference                                                                 |
|--------------|-------------------------|-------------|----------------------------------------------------------------------------------------|
| UK Stem Cell Bank | Comprehensive         | UK          | http://www.nibsc.org                                                                 |
| National Centre for Cell Science Cell Repository | Comprehensive         | USA         | http://www.nccs.res.in                                                                 |
| WiCell International Stem Cell Bank        | Comprehensive         | USA         | https://www.wicell.org/home/stem-cells/stem-cells.cmsx                                 |
| Cord Blood Registry        | Cord blood/cord tissue stem cells | USA         | https://parentsguidecordblood.org/crbanks/cord-blood-registry                          |
| Australian Cord Blood Bank | Cord blood            | Australia   | http://www.stemlife.com.au                                                             |
| BioEden        | Child milk tooth stem cells | USA         | https://us.bioeden.com                                                                 |
| Human Pluripotent Stem Cell Registry | Human pluripotent stem cell | Global registry | http://hpscreg.eu                                                                     |
| Swiss Stem Cell Bank        | Cord blood            | Switzerland | http://parentsguidecordblood.org/en/bank/swiss-stem-cell-bank                           |
| China National GeneBank    | Comprehensive         | China       | https://en.genomics.cn/en-gene.html                                                     |
| National Stem Cell Resource Center | Comprehensive       | China       | http://www.bjscb.cn/dms/gyygb/4.html                                                    |
| Shanghai East Hospital Biobank | Comprehensive       | China       | http://easthospital.cn/biobank/Home/Index                                               |
| China Stem Cell Group       | Cord blood            | China       | http://www.chinacordblood.org                                                           |
| Boyalife        | Cord blood            | China       | https://www.boyastem.com/about.html                                                     |
The principles of “5C” for the establishment of the stem cell bank

The establishment of the stem cell bank is conducive to the researches of stem cells, providing a stable source of seed cells and accelerating the study and development of stem cell technology, which promotes the clinical research processes of stem cells and the conversion applications of stem cells. At the same time, high-quality stem cell banks are not only the premise of clinical applications of stem cell products, but also the key success factors of the stem cell industry, providing stem cell researches and extensive applications with necessary resources [14]. Therefore, based on a good international environment, speeding up the establishment of the standardized stem cell bank is the core and key to standing at the strategic highland of international high-quality resources. Based on summarizing the relevant international norms and existing experiences in establishing stem cell banks, we proposed the principles of “5C” for the establishment of modern stem cell banks (Fig. 1).

Principle of informed consent

The principle of informed consent refers to the process, in which patients or healthy volunteers voluntarily donate body tissues or cells and allow researchers to conduct relevant studies [15]. According to the “Informed Consent/Institutional Review Boards: 21 CFR Parts 50/56” issued by the Food and Drug Administration (FDA), donors must first sign an informed consent form. The General Medical Council (GMC) has also stressed the need to ensure that patients have agreed to participate in teaching or researching before any specific test or research. While the types of stem cells and their purposes vary, stem cell banks must ensure that donors are voluntary, documented, and that the information about donors is kept private.

Confidentiality principle

Confidentiality means that managers of the stem cell bank are forbidden to disclose any specific information about the donors. The sources of the tissues must be kept secretly by the staff of the stem cell bank, to decouple irreversibly the identity of the tissues from the samples. Researchers sometimes hold indirect links (such as ID numbers) between the tissues and the donors that can be used to locate the tissue donors in an emergency [3]. Besides, a sound management system and punitive measures should be made to maximize the prevention of the insiders of the stem cell banks from maliciously disclosing the donors’ information.

Conformity principle

The conformity of stem cells provides the most basic guarantee for the application of stem cells in basic researches and clinical and commercial applications [16]. To ensure that the quality of stem cells in the bank meets the application standards, the International Stem Cell Bank Initiative (ISCBI) was held in Boston in 2017, and the experts attending the meeting emphasized that the quality control of the stem cell products should be put into the top priority [17]. Therefore, there must be a strict management system to manage and evaluate the quality of the stem cell bank. This system should include the processes of selecting the stem cell donors, storage ethical processes of certain cells, personnel training, the quality and functions of the equipment of the stem cell bank, the culturing and freezing materials used on the stem cells, international regulatory standards, and the guidelines and principles accepted by the stem cell bank industry, such as ISCBI Guidelines and the Organization for Economic Co-operation and Development (OECD) Principles [18, 19].

Contamination-free principle

In the processes of long-term storage and application of stem cells, it is very important to prevent cross-contamination of cell lines and microbial contamination [20]. First, raw materials should be prevented from exogenous contamination, strict screening standards and procedures should be established for the tissues and cells of donors, and a comprehensive risk assessment for pathogen types (such as HIV) that may introduce contamination risks should be conducted [21, 22]. Secondly, mycoplasma infection should be prevented. The infection rate of mycoplasma reported by cell line testing companies accounts for about 8% of the total test samples [23]. The researchers suggested that the following measures could be taken to prevent the potential
contamination risks during the long-term storage of stem cells: (1) select gas-phase liquid nitrogen containers, (2) set the safety helmet when the sample must be immersed in liquid nitrogen containers, (3) use internal thread construction and double bags to store the stem cell samples, (4) ensure the complete closure of the storage containers and the shelf lives of the products, (5) set isolation storage areas to control the spread of pathogens, (6) keep storage containers in a clean environment to reduce the risks of surrounding pollution, (7) ensure clean liquid nitrogen sources, (8) strengthen professional training for laboratory personnel and raise their awareness of preventing microbial pollution, and (9) inspect samples randomly at regular intervals to ensure the purity of the stem cell samples [24].

Commonwealth principle
From 2017 to 2022, the global stem cell market has grown at an annual rate of 36.52%, and the stem cell industry is processing into a period of comprehensive and rapid development. Many experts believe that profiting from human tissues violates the principles of altruistic donation on which we depend and that the economic rewards for donors should not be offered, as this could undermine the principles of informed consent discussed here. Many countries in the world have also made corresponding policies. The European Union required the Stem BANCC to provide specific data on its stem cell production to European researchers at no cost [25]. In the UK, both the GMC and the Medical Research Council (MRC) explicitly prohibited the use of human tissues for economic interests.

Stem cell drugs
Researches on stem cell drugs not only provided people with rich imagination space, broad application prospects, and important theoretical values, but also contain huge business opportunities. In the USA, federal and non-federal funding agencies have spent billions of dollars on clinical trials, and they believe that stem cell drugs are a promising therapy for Alzheimer’s and Parkinson’s disease-related disorders [22]. Therefore, stem cell drugs have attracted the attention and investment of businesses and governments.

China has also laid down a series of national policies to promote the clinical application of stem cells. In 2017, China formulated the technical management specifications for the transplantation of hematopoietic stem cells. On August 21, 2015, the National Health Commission of the People’s Republic of China and the National Medical Products Administration (NMPA) jointly made the policy for the administration of clinical researches or clinical trials on stem cell therapies. By March 19, 2020, new five clinical research institutions and four clinical research projects on stem cells had been registered in China. Table 2 shows that many kinds of stem cell drugs had been approved in the world till now. As of 2016, about 1000 clinical trials on stem cells had been conducted globally [26]. And excitedly, some stem cell-based products have been approved in some countries (Table 2).

Multiple applications of stem cell banks in the management of refractory sports injuries
The stem cell therapy products represented by mesenchymal stem cell (MSC) preparation are expected to become the third type of disease treatment products after drugs and medical devices and may play a good effect in some diseases that cannot be cured by existing treatment methods, opening up new ways for diseases [27]. In the field of sports medicine, the combination of stem cells and tissue engineering scaffolds provides a new therapeutic option for the regeneration and repair of the cartilage, meniscus, and ligament.

Tissue-engineered cartilage
Articular cartilage plays an important role in joints. But due to the lack of nerves and blood vessels, articular cartilage regeneration is very limited [28]. The development and progress of tissue engineering have brought new hope for the repair of cartilage injury and even myocardial infarction [29]. And the first step in tissue-engineered cartilage research is to identify appropriate seed cells to promote cartilage regeneration. For cartilage regeneration, the most used therapeutic stem cells are MSCs [30–36].

Tissue-engineered meniscus
Stem cells are popular in the field of tissue-engineered meniscus due to their autocrine ability of cytokine and growth factors that favors tissue regeneration [37]. In recent years, stem cell-based TEM approaches have been widely used in meniscus regeneration, which obtained encouraging results of meniscus regeneration. Chang et al. have demonstrated that protein-releasing polymeric scaffolds inducing endogenous stem cells regenerated the knee meniscus, with the maintenance of the meniscal structure and function, providing evidence for a chondroprotective effect in a sheep model. Of note, this highlights the key roles of MSCs and growth factors in successful meniscal healing to generate normal cellular phenotypes [38].

TEM also brought good news to patients in clinics. Whitehouse et al. tested MSCs/collagen scaffold in a sheep meniscal tear model with promising results after 13 avascular meniscal tears and reported a case of 5 patients where undifferentiated mesenchymal stem cells were injected onto a collagen scaffold and sutured into
| Year  | Corporation                          | Stem cell type                                           | Clinical application                                           | Name of bank                                                                 |
|-------|--------------------------------------|----------------------------------------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------|
| 2009.12 | Prochymal/Osiris Therapeutics, Inc., USA | Mesenchymal stem cells from human allogeneic bone marrow | Graft versus host disease (GVHD) and Crohn's disease           | American Food and Drug Administration (FDA)                                  |
| 2010.07 | MPC/Mesoblast                       | Autologous mesenchymal precursor cells                    | Bone reconstruction                                            | Production permit of Therapeutic Goods Administration (TGA) in Australia     |
| 2011.07 | Hearticellgram-AMI/FCB-Pharmicell    | Autologous bone marrow mesenchymal stem cells             | Acute myocardial infarction                                   | Food and Drug Administration in South Korea                                  |
| 2011.11 | Hemacord/New York Blood Center      | Cord blood hematopoietic progenitor cells                 | Hereditary or acquired hematopoietic disease                  | Biological License of American Food and Drug Administration (FDA)           |
| 2011.11 | MultiStem/Athersys Inc., USA        | Allogeneic bone marrow stem cell                          | Type I mucopolysaccharidosis                                  | American Food and Drug Administration (FDA)                                  |
| 2012.01 | Cartistem/Medi-post                 | Mesenchymal stem cells from the cord blood                | Degenerative arthritis and cartilage damage in the knee joint | Food and Drug Administration in South Korea                                  |
| 2012.01 | Cuepistem/Anterogen                | Mesenchymal stem cells from autologous fat                | Crohn's disease complicating anal fistula                     | Food and Drug Administration in South Korea                                  |
an avascular meniscal tear. Three out of five patients reported positive outcomes beyond 12 months with significantly improved clinical scores and subsequent magnetic resonance imaging (MRI) scans. We knew that undifferentiated autologous MSCs seeded onto collagen scaffolds can be safely implanted into patients with a torn meniscus, so avoiding the need for meniscectomy [39]. With the advancements in tissue engineering and stem cell-based technologies, new therapeutic options for patients will potentially emerge.

**Tissue-engineered ligament**

Stem cells are seed cells emerging from tissue-engineered ligaments in recent years. Compared with adult cells, stem cells have many advantages. Taking mesenchymal stem cells as an example, they have the potential of multi-differentiation [40] and have been widely used in animal models of bone injury, ligament injury, and other diseases [41, 42]. Studies have found that bone marrow mesenchymal stem cells can be directed to differentiate into ligamentoid cells, promote vascularization of ligament tissue, and repair and regenerate damaged ligaments [43].

In summary, stem cells represent a significant cell source for tissue engineering under certain conditions, including the presence of suitable microenvironments and bioactive factors. However, stem cells still have defects such as induced differentiation, expensive proliferation, and low efficiency in vitro, so further research is needed.

**Prospects of the application of stem cell banks in the management of refractory sports injuries**

Although currently there are not many applications from stem cells clinically available for sports injury treatment, the rapid development and application of TEC, TEM, and TEL have greatly expanded the feasibility and innovation of the clinical application of stem cells in the management of sports injuries. The researches on stem cell are undoubtedly of significance for the management of athletes’ refractory injuries and have potential therapeutic values for injuries of the cartilages, menisci, and ligaments. At the same time, with the continuous development such as 3D printing, the future stem cell biotechnology relying on the stem cell bank may completely overturn the traditional medical concepts and bring unexpected “surprises” and “rewards” to the treatment of refractory sports injuries. Therefore, stem cells have the potential to change the fate of each of us and even the entire human society.

But there is a long way to go, such as how to overcome immune rejection and control the optimal growth, proliferation, and differentiation conditions of stem cells in vivo. The modernization and systematic management of the stem cell banks have maximized the application boundary of stem cells and brought infinite benefits to human beings, but at the same time, there are some hidden dangers. Along with the establishment of stem cell banks, there will inevitably be some worrying things. If people use stem cell technology to produce stem cell stimulants, they will transplant the stem cells of mammals with sports specialties to athletes to improve their competitive performances. This will involve a series of ethical issues that even go against the Olympic spirit of “fair competition.” In the future, it will be an important research direction to strengthen the ethical review of the applications of stem cell banks and improve the detection technology.

**Abbreviations**

ACL: Anterior cruciate ligament; BMMSCs: Bone marrow-derived MSCs; FDA: Food and Drug Administration; GMC: General Medical Council; HLA: Human leukocyte antigen; ISCBI: International Stem Cell Bank Initiative; MRC: Medical Research Council; MRI: Magnetic resonance imaging; MSCs: Mesenchymal stem cells; OECD: Organization for Economic Cooperation and Development; PBMSCs: Peripheral blood-derived MSCs; TEC: Tissue-engineered cartilage; TEL: Tissue-engineered ligament; TEM: Tissue-engineered meniscus

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Bao-Shi Fan: collection and/or assembly of data and data analysis and interpretation. Yang Liu: collection and/or assembly of data and data analysis and interpretation. Ji-Ying Zhang: data analysis and interpretation. You-Rong Chen: administrative support. Meng Yang: data analysis and interpretation. Jia-Kuo Yu: conception and design, financial support, manuscript writing. The authors read and approved the final manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (no. 81630056, 51773004, 51920105006).

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Sports Medicine Department of the Institution of Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, No. 49 North Garden Road, Beijing 100191, China. 2Institute of Sports Medicine of Peking University, No. 49 North Garden Road, Beijing 100191, China. 3School of Clinical Medicine, Weifang Medical University, No.7166 West, Baotong Road, Weifang 261053, Shandong, China.
References

1. Sun C, et al. Fundamental principles of stem cell banking. Adv Exp Med Biol. 2016;915:1–45. https://doi.org/10.1007/978-3-319-45657-3_3.

2. Clevers H. STEM CELLS. What is an adult stem cell? Science. 2015;350(6266):1319–20. https://doi.org/10.1126/science.aad0716.

3. Stacey G. Stem cell banking: a global view. Methods Mol Biol. 2017;1590:3–10. https://doi.org/10.1007/978-1-4939-6921-0_1.

4. Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13(7):859–66. https://doi.org/10.1016/j.rmed.2018.07.009.

5. Sevilla A, Forero E, Zimmer M, Martinez H, Reggio K, Paull D, et al. Derivation and characterization of the NIH registry human stem cell line NYSCF-100 line under defined feeder-free conditions. Stem Cell Res. 2018;29:99–102. https://doi.org/10.1016/j.scr.2018.03.017.

6. Masuya H, Ushida D, Nakata H, et al. Establishment and application of information resource of mutant mice in RIKEN BioResource Research Center. Lab Anim Res. 2021;37(6). https://doi.org/10.1186/s42826-020-00068-8.

7. Azuma K, Yamanaoka S. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Regen Ther. 2016a;4:36–47. https://doi.org/10.1016/j.reth.2016.01.009.

8. Veiga A, Aran B, Raya A, Messinis I, Mahmood T. EBCOG position statement: ethics of stem cell research. Eur J Obstet Gynecol Reprod Biol. 2020;247:15–19. https://doi.org/10.1016/j.ejogrb.2020.01.017.

9. Schultz MB, Sinclair DA. When stem cells grow old: phenotypes and rejuvenation strategies for stem cell-based therapies. Regen Med. 2017;12:597–609. https://doi.org/10.1016/j.stem.2017.01.008.

10. Neves J, Sousa-Victor P, Jasper H. Rejuvenating strategies for stem cell-derived therapies in aging. Cell Stem Cell. 2018;20(2):161–70. https://doi.org/10.1016/j.stem.2017.01.008.

11. Kwon H, Brown WE, Lee CA, Wang D, Paschos N, Hu JC, et al. Surgical and tissue engineering strategies for articular cartilage and meniscus repair. Nat Rev Rheumatol. 2019;15(9):550–70. https://doi.org/10.1038/s41584-019-0255-1.

12. Hohen GM, Hu JC, James RA, Athanasiou KA. Self-assembly of fibrochondrocytes and chondrocytes for tissue engineering of the knee meniscus. Tissue Eng. 2007;13(5):939–46. https://doi.org/10.1089/teng.2006.0116.

13. WilmutI, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, et al. Development of a global network of induced pluripotent stem cell haplobanks. Regen Med. 2015;10(3):235–8. https://doi.org/10.1016/j.rmed.2015.01.011.

14. West CC, Murray IR, González ZN, Hindle P, Hay DC, Griffin A, et al. Cell banking for pharmaceutical research. Drug Discov Today. 2014;19(10):1518–29. https://doi.org/10.1016/j.drudis.2014.05.006.

15. Hayakawa T, Aoi T, Umewaka A, Ozawa K, Sato Y, Sawada Y, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. Regen Ther. 2015;2:59–67. https://doi.org/10.1016/j.reth.2015.05.002.

16. Hayakawa T, Aoi T, Umewaka A, Ozawa K, Sato Y, Sawada Y, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells. Regen Ther. 2015;2:109–22. https://doi.org/10.1016/j.reth.2015.05.001.

17. Kono K, Takada N, Yasuda S, Sawada R, Niihi S, Matsuyama A, et al. Characterization of the cell growth analysis for detection of immortal cellular impurities in human mesenchymal stem cells. Biologicals. 2015;43(2):146–9. https://doi.org/10.1016/j.biologicals.2014.11.007.

18. Hasebe-Takada N, Kono K, Yasuda S, Sawada R, Matsuyama A, Sato Y. Application of cell growth analysis to the quality assessment of human cell-processed therapeutic products as a testing method for immortalized cellular impurities. Regen Ther. 2016;3:494–54. https://doi.org/10.1016/j.reth.2016.06.005.

19. Arrieta AP, Ravichandran J, Carkaci-Sall N. Neural regeneration therapies for Alzheimer’s and Parkinson’s disease-related disorders. Biochim Biophys Acta Mol Basis Dis. 1866;2020(4):165506.

20. Thiret S, de Coninck H, Lefebvre V, Delaunay V, Legendre D, Rozenzweig R, et al. Cell banking in neurodegenerative disease research. Neurodegener Dis. 2018;15:23–7. https://doi.org/10.1159/000495278.

21. Lee CH, et al. Protein-releasing polymeric scaffolds induce fibrochondrocytic fibrochondrocytes and chondrocytes for tissue engineering of the knee meniscus regeneration strategies: a review on recent advances. Curr Stem Cell Rep. 2015;1(2):110–21.

22. Pillai MM, Gopinathan J, Selvakumar R, Bhattacharyya A. Human knee meniscus cellular impurities. Regen Ther. 2016;5:49-50. https://www.sciencedirect.com/science/article/pii/S221422451630008X.

23. Lee CH, et al. Protein-releasing polymeric scaffolds induce fibrochondrocytic fibrochondrocytes and chondrocytes for tissue engineering of the knee meniscus regeneration strategies: a review on recent advances. Curr Stem Cell Rep. 2015;1(2):110–21.

24. Lee CH, et al. Protein-releasing polymeric scaffolds induce fibrochondrocytic fibrochondrocytes and chondrocytes for tissue engineering of the knee meniscus regeneration strategies: a review on recent advances. Curr Stem Cell Rep. 2015;1(2):110–21.

25. Lee CH, et al. Protein-releasing polymeric scaffolds induce fibrochondrocytic fibrochondrocytes and chondrocytes for tissue engineering of the knee meniscus regeneration strategies: a review on recent advances. Curr Stem Cell Rep. 2015;1(2):110–21.
42. Choi K, Ortega MT, Jeffery B, Riviere JE, Monteiro-Riviere NA. Oxidative stress response in canine in vitro liver, kidney and intestinal models with seven potential dietary ingredients. Toxicol Lett. 2016;241:49–59. https://doi.org/10.1016/j.toxlet.2015.11.012.

43. Nau T, Teuschl A. Regeneration of the anterior cruciate ligament: current strategies in tissue engineering. World J Orthop. 2015;6(1):127–36. https://doi.org/10.5312/wjo.v6.i1.127.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.